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Obesity and diabetes are increasing in prevalence worldwide. Despite excessive dietary consumption, obese individuals have high
rates of micronutrient deﬁciencies. Deﬁciencies of speciﬁc vitamins and minerals that play important roles in glucose metabolism
and insulin signaling pathways may contribute to the development of diabetes in the obese population. This paper reviews the
current evidence supporting this hypothesis.
1.Introduction
Obesity is highly prevalent both in the United States and
worldwide and is projected to surpass tobacco use as the
mosteconomicallyimportantmodiﬁableriskfactorinpublic
health and disease [1–3]. Multiple genetic, environmental
and behavioral factors contribute to the increasing trend in
obesity [1, 3]. The increased availability of low-cost, high-
calorie, nutrient-poor foods over the past four decades is a
key component to the rise in obesity worldwide [3]. Modern
agriculture and food processing techniques lead to a relative
reduction in the micronutrient content of common foods
[4]. Despite an excess of dietary calorie intake, obese individ-
uals have relatively high rates of micronutrient deﬁciencies
[5, 6].
The importance of certain micronutrients as cofactors in
glucose metabolic pathways, pancreatic β-cell function and
in the insulin signaling cascade suggests that deﬁciency in
these micronutrients may play a role in the development of
type 2 diabetes.
The risk of type 2 diabetes is increased 4-fold in obese
patients [7]. The causal relationship of obesity and diabetes
is complex. Increased insulin resistance, incretin hormone
resistance, oxidative stress, pancreatic β-cell dysfunction,
and genetic and behavioral factors all contribute to the de-
velopment of diabetes in obese individuals [8]. Speciﬁc
micronutrient deﬁciencies in obese individuals may also in-
ﬂuence the development of type 2 diabetes.
2.VitaminD
High rates of vitamin D insuﬃciency and frank deﬁciency
have been reported in obese individuals and in diabetics. The
prevalenceofvitaminDinsuﬃciency(deﬁnedas<30mg/dL)
in obese individuals ranges from 80–90% [5, 9]. While some
controversy exists over treatment targets in individuals with
mild insuﬃciency of vitamin D especially for the purported
extraskeletal eﬀects of vitamin D supplementation, [10, 11]
a signiﬁcant amount of evidence suggests there may be some
beneﬁcial eﬀect in using vitamin D supplementation for im-
provement in glucose metabolism and insulin signaling in
patients with type 2 diabetes or impaired glucose tolerance
[12].
Preclinical evidence for the role of vitamin D in insulin
secretion and function includes the presence of vitamin D
receptors in human pancreatic β-cells, the detection of 1-α-
hydroxylase activity, and insulin gene transcription respon-
siveness to vitamin D in pancreatic β-cells [13–16]. In
vitamin D deﬁcient animals, pancreatic β-cell dysfunction
is noted, which is restored with vitamin D supplementa-
tion [17–19]. Many epidemiologic studies demonstrate an
inverse relationship between 25-hydroxyvitamin D level and2 ISRN Endocrinology
prevalence of type 2 diabetes [20–25]. Seasonal ﬂuctuations
in glycemic control in type 2 diabetics may also be due in
part to ﬂuctuations in vitamin D levels, though behavioral
diﬀerences may also explain these ﬁndings [26, 27].
Recent reviews and metaanalyses of clinical trials suggest
apot entialeﬀectofvitaminDsupplementationonthedevel-
opment of type 2 diabetes in high-risk individuals [12, 16,
28]. Three of ﬁve randomized trials demonstrate improve-
ments in insulin sensitivity with vitamin D supplementation
insubjectswithinsulinresistanceorimpairedfastingglucose
[29–31]. One study showed improved oral glucose tolerance
and insulin sensitivity in 71 obese males supplementation
with 120,000i.u. of cholecalciferol or placebo every 2 weeks
a f t e r6w e e k so ff o l l o w u p[ 29]. A second trial showed im-
provementininsulinsensitivityanddecreasedfastinginsulin
levels in 81 vitamin D deﬁcient subjects with baseline insulin
resistance given 4,000i.u. cholecalciferol daily or placebo
[31]. In the third trial, subjects with impaired fasting glucose
showed stability in fasting glucose levels after three years of
dailysupplementationof700i.u.ofcholecalciferolcompared
to an increase in fasting glucose in the placebo group [30].
TwotrialsfailedtoshoweﬀectofvitaminDsupplementation
[32, 33]. One of these used only low doses of vitamin D
(400i.u. daily) that may not have been adequate; over 89%
of participants did not achieve normal levels of vitamin D by
the end of the trial [32]. Based on the results these ﬁve stud-
ies, patients at risk for development of type 2 diabetes may
beneﬁt from vitamin D supplementation.
The use of vitamin D in patients already diagnosed with
type 2 diabetes has also been investigated. Of four recently
published randomized trials, two demonstrate improve-
ments in glycemic control [33–36]. In one trial, 92 early type
2 diabetics (deﬁned by glycosylated hemoglobin ≥5.8% and
2-hour postprandial glucose ≥140mg/dL) were randomized
to receive 2,000i.u. of cholecalciferol or placebo daily for
4w e e k s[ 34]. Signiﬁcant improvements in the measured
glucose disposition index were noted in the treatment group.
In another trial, 90 type 2 diabetic patients given 1,000i.u.
cholecalciferol or placebo daily for 12 weeks demonstrated
decreased glycosylated hemoglobin by 0.4%, decreased fast-
ing glucose by 13mg/dL, improved insulin sensitivity, and 1-
2kg weight loss in the treatment group [35].
In one of the trials that demonstrated negligible eﬀect
of vitamin D supplementation in type 2 diabetics, patients
given single dose of 300,000i.u. of cholecalciferol found no
change in fasting glucose, fructosamine, or insulin sensi-
tivity despite normalization of plasma 25-hydroxyvitamin
Dl e v e l s[ 33]. However, adequate levels of serum 25-hy-
droxyvitamin D were not achieved in this trial. The average
25-hydroxyvitamin D level at the end of followup was
16ng/dL.
The other negative study was a randomized trial with 6
weeks of followup in which 32 diabetic patients were given
40,000i.u. of cholecalciferol or placebo every two weeks and
showed no diﬀerence in glycosylated hemoglobin, fasting,
glucose or insulin sensitivity [36]. Subjects in both treatment
arms had a relatively high baseline 25-hydroxyvitamin D
level in this trial (24ng/dL), which may have contributed to
the negative results.
The use of vitamin D supplementation speciﬁcally for
improvements in insulin sensitivity remains a controversial
issue. There are presently ten ongoing clinical trials evaluat-
ing the use of vitamin D supplementation in type 2 diabetic
patients and patients with impaired glucose tolerance, which
may provide further guidance on this issue. Given the high
rates of vitamin D insuﬃciency in the obese population and
the observed beneﬁts, clinicians may consider vitamin D
supplementation in this population.
3. Chromium
Chromium was recognized as an essential trace metal re-
quired in the insulin signal cascade through animal dietary
experiments that were ﬁrst performed in the 1950s [37,
38]. Molecular and cell culture studies demonstrate that
chromiumboundtotheoligopeptidechromodulinenhances
the tyrosine kinase activity of the insulin receptor and in-
hibits phosphotyrosine phosphatase activity, thereby ampli-
fying the intracellular insulin signal cascade [39, 40].
Chromium deﬁciency in humans has been identiﬁed in
severely malnourished patients who demonstrate severe in-
sulin resistance, hyperglycemia, hypertriglyceridemia, and
painful neuropathy. In published case reports, these symp-
toms and signs completely and rapidly resolve after the
administration of chromium [41–44]. As a result of these
ﬁndings, the inclusion of chromium in parenteral nutrition
formulas has become standard [45].
The main dietary sources of chromium include yeast,
meats, and wheat germ. The use of stainless steel pots and
utensils increases the chromium content of food as traces of
chromium are liberated from the steel during preparation.
Bodystoresofchromiumareintracellular,mainlyintheliver.
Individuals with type 2 diabetes have 20–40% lower blood
chromium levels and 40–50% lower chromium levels mea-
sured in scalp hair compared to healthy controls [46–49].
Chromiumdeﬁciencyratesinobeseindividualsarecurrently
not available.
A number of clinical trials have investigated the role of
oral chromium supplementation in patients with type 2 dia-
betes, insulin resistance, and the metabolic syndrome [50,
51]. In general, the results of these trials show only modest
improvements in markers of insulin resistance and glucose
metabolism. The greatest eﬀects are noted in trials that
administer higher doses and supplement with compounds
such as chromium picolinate that provide a higher bioavail-
ability of chromium. A review of 15 trials using chromium
picolinate notes consistent improvements in glycemic con-
trol in 13 of the 15 trials, with an overall average decrease in
glycosylated hemoglobin of 0.95% [52].
As with many supplements, the use of chromium sup-
plementation in diabetic patients or in patients at risk for
diabetes is controversial. The results of clinical trials that
administer high doses of high bioavailability chromium sug-
gest that supplementation with chromium may improve in-
sulin resistance and glycemic control in diabetes [52]. Re-
cently, the United States Food and Drug Administration
releaseaQualityHealthClaimregardingtheuseandsafetyof
chromium picolinate for the treatment of insulin resistanceISRN Endocrinology 3
[53]. This therapy may be beneﬁcial in obese patients at risk
for diabetes.
4.Biotin
Biotin is a water soluble vitamin that serves as a cofactor
for carboxylase enzymes in fatty acid synthetic pathways, the
citricacidcycle,andaminoacidmetabolism[54].Inaddition
to its biochemical function, circulating biotin regulates gene
expression [55]. Prevalence data regarding rates of biotin
deﬁciency in obese individuals or in diabetic patients are not
presently available. However, patients with type 2 diabetes
demonstrate lower circulating levels of biotin compared to
healthy controls and an inverse relationship between biotin
level and fasting plasma glucose has been reported [56, 57].
Animal studies demonstrate the development of insulin
resistance in biotin deﬁcient rats that resolves with biotin
replacement [62]. At least part of the underlying mechanism
of this phenomenon involves biotin-induced hexokinase
gene expression that increases hepatic glucose uptake [63,
64].Biotinalsoregulatestranscriptionoftheinsulinreceptor
and improves pancreatic β-cell function [65, 66].
To date, only a few human trials evaluating the eﬃcacy of
biotin supplementation on glycemic control have been con-
ducted. In one longitudinal study, diabetic patients treated
for 28 days with 15mg biotin supplements had improve-
ments in fasting glucose and insulin levels [54, 67]. Two
placebo-controlled trials studied the use of combined biotin
and chromium supplementation in type 2 diabetic subjects
[68, 69]. Improvements in glucose metabolism were noted in
both trials. One trial demonstrated signiﬁcant improvement
in oral glucose tolerance and reduction in fructosamine after
4w e e k so ff o l l o w u p[ 69]. The second trial demonstrated
a reduction in glycosylated hemoglobin of 0.5% from a
baseline of 8.7% in 447 subjects over 90 days [68].
With the promising results of these early studies, the po-
tential beneﬁts of biotin supplementation may be considered
in diabetic and obese patients.
5.Thiamine
Thiamine is an essential micronutrient that acts as a co-
factor for several key enzymes in glucose and aminoacid me-
tabolism including transketolase, pyruvate dehydrogenase,
α-ketoglutarate dehydrogenase, and α-keto acid decarboxy-
lase [70]. The latter three are important regulatory enzymes
that serve to mediate glycolysis, the citric acid and the pen-
tose phosphate shunt pathways, respectively [70]. Thiamine
deﬁciency leads to a relative reduction in these metabolic
pathways and to increases in the polyol, hexosamine, protein
kinase C, and advanced glycosylated end-product pathways
of glucose metabolism that can lead to endothelial dysfunc-
tion and potentially worsen type 2 diabetes [71]( Table 1).
Thiamineisabsorbedintheproximalsmallbowelmainly
through active transport [72]. The recommended daily
intake of thiamine is 1.2mg, approximately 0.5mg per
1000kcal consumed [73]. Important food sources of thi-
amine include pork, red meat, wheat germ, eggs, ﬁsh, and
legumes [73]. Thiamine is virtually absent in food products
Table 1: Prevalence of micronutrient deﬁciencies in obesity and
diabetes [5, 6, 46, 58–61].
Micronutrient
Prevalence of deﬁciency
Obesity Type 2 diabetes
Thiamine B1 15–29% 17–79%a
Pyridoxine B6 0–11% —
Cobalamin B12 3–8% 22%
Folic Acid 3-4% —
Ascorbic acid C 35–45% —b
Vitamin A 17% —
Vitamin D 80–90%c 85–90%c
Vitamin E 0% 0%
Zinc 14–30% —
Chromium — 20–40%
Selenium 58% —
—Prevalence data not available
aData includes type 1 diabetic patients
bD e c r e a s e dl e v e l so fa s c o r b i ca c i dh a v eb e e nr e p o r t e di nd i a b e t e s
cPrevalence reﬂects rates vitamin D insuﬃciency.
containing reﬁned carbohydrates such as milled rice and
simple sugars, yet the metabolism of these foods requires
relatively high amounts of thiamine and may lead to deple-
tion [74]. In subjects on thiamine deﬁcient diets, total body
thiamine stores can be depleted within 2-3 weeks [74].
Severe deﬁciency of thiamine can lead to wet or dry ber-
iberi or Wernicke encephalopathy, depending on the tissues
involved. Moderate deﬁciency of thiamine may aﬀectglucose
metabolism and impact diabetes and related complications
[71].
Thiamine deﬁciency measured by direct plasma levels
of thiamine or by elevated erythrocyte transketolase activity
has been observed in 15–29% of obese individuals planning
to undergo weight loss surgery [75, 76]. The prevalence of
thiamine deﬁciency has been reported in 17–79% of diabetic
patients, although these studies include both type 1 and type
2 diabetic patients [77–79]( Table 1).
Evidence for the eﬀect of thiamine supplementation to
reduce the risk and severity of type 2 diabetes has been
demonstrated in a number of studies. Cultured endothelial
cells demonstrate reduced production of reactive oxidative
species and improved function in high glucose concentra-
tionsinthepresenceofthiamine[80,81].Bothofthesechar-
acteristics are expected to reduce the risk of diabetic com-
plications and possibly reduce the risk of diabetes itself [8].
In a double-blind crossover trial, the administration of
benfotiamine, a lipid soluble thiamine analogue, improved
endothelial function, reduced markers of oxidative stress
and reduced levels of advanced glycosylated end-products
followingatestmealintype2diabeticpatients[82].Amount
of dietary thiamine intake has been correlated with levels of
endothelial progenitor cells in type 2 diabetic patients [83].
Long-term studies investigating the use of thiamine sup-
plementation in diabetic patients have not been performed.
The potential exists for thiamine supplementation to modify
the course of diabetes by modulation of glucose metabolic4 ISRN Endocrinology
pathways. Given high rates of thiamine deﬁciency in obese
individuals and diabetic patients, supplementation may be
considered.
6.AntioxidantVitamins
Despite importance of reactive oxygen species and increased
oxidative stress in the development, progression, and asso-
ciated complications of type 2 diabetes, trials using antiox-
idant treatment in both diabetic patients and patients with
impaired fasting glucose have been largely disappointing and
indicate little to no overall eﬀect [84–86]. As a result, the
routine supplementation with vitamin E, vitamin C, and
vitaminAindiabeticpatientsiscurrentlynotrecommended.
Vitamin E consists of a family of lipid soluble antioxidant
compounds, of which α-tocopherol is the most abundant in
the diet [87]. In contrast to other micronutrients discussed
in this paper, obese and diabetic individuals have low rates of
vitamin E deﬁciency. Studies in these groups fail to ﬁnd any
individuals that are vitamin E deﬁcient [5, 9].
The use of vitamin E was studied in the Heart Outcome
Prevention Evaluation (HOPE) trial, in which 3654 diabetic
patients were randomized to receive 400i.u. of α-tocopherol
or placebo [88]. After 4.5 years of followup, no diﬀerences
in cardiovascular outcomes, nephropathy, dialysis, or retinal
laser therapy were seen between treatment groups. Several
small trials show no diﬀerences in glycemic control with
vitamin E supplementation in type 2 diabetics [89–92].
Although there are a few published trials that suggest modest
improvements in glycosylated hemoglobin, [93, 94]ar e c e n t
metaanalysis of 9 studies demonstrates no appreciable eﬀect
of vitamin E supplementation on glycemic control in type 2
diabetic patients [86].
Vitamin C or ascorbic acid is a water soluble antioxidant
vitamin that does not have signiﬁcant body stores. Limited
intakeoffruitsandvegetablescanleadtorapiddepletion[5].
Plasma vitamin C levels correlate inversely with body mass
index and deﬁciency of vitamin C is reported in 35–45%
of obese individuals planning to undergo bariatric surgery
[58, 95]. Diabetic patients have lower dietary intake and
lower plasma levels of vitamin C than healthy controls [96].
In a population study of 232,007 older adults, vitamin
C supplementation was associated with mildly lower rates
of type 2 diabetes in a dose responsive manner. Individuals
that took 500mg daily had a 9% reduction in prevalence
of diabetes [97]. Data from the National Health and Nutri-
tion Exam Study (NHANES) III cohort demonstrates sig-
niﬁcantly lower plasma levels of vitamin C in type 2 dia-
betics [98]. These results should be weighed carefully as pop-
ulation-based nutritional studies often have confounding
factors.
Few clinical trials have examined the use of vitamin C
supplementation in type 2 diabetic patients. One small
randomized trial in 20 diabetic subjects demonstrated that
1000mg daily oral vitamin C supplementation improved
glucose disposal rates after 4 months [99]. A second trial
failed to show improvement in glucose metabolism or in-
sulin resistance with 800mg daily vitamin C supplementa-
tion [100]. In this study, plasma levels of vitamin C rose
signiﬁcantly;however,adequateplasmavitaminClevelswere
not achieved.
Further studies in diabetic patients and in those at risk
for developing diabetes may help to elucidate the role of
vitamin C supplementation in this population. The high rate
of vitamin C deﬁciency in obese individuals suggests that
supplementation may be beneﬁcial. Increasing dietary intake
of fruits and vegetables can also address this deﬁciency and is
currently recommended as part of a lifestyle intervention for
the prevention and treatment of type 2 diabetes [101].
7. Conclusion
As with nearly all biochemical processes, glucose metabolism
and insulin signaling require cofactors and vitamins that are
essential in the diet. Deﬁciencies in any of these micronutri-
ents have potential to impair glucose metabolism and cause
insulin resistance. Clinical evidence supporting this hypoth-
esis regarding the metabolic eﬀects of speciﬁc deﬁciencies
including vitamin D, chromium, biotin, thiamine and vita-
min C is mounting. Unlike vitamin E, which has little to no
proven clinical eﬀect when given as a supplement, these vita-
mins are known to be deﬁcient at relatively high rates in
obese individuals and in diabetic patients. Clinicians should
consider addressing possible deﬁciencies of these micronu-
trients when advising obese patients who are at risk for the
development of type 2 diabetes. The medical care plan for
obesity should include lifestyle changes, healthy food choices
with high-nutrient content foods as part of a balanced ap-
proach for the prevention of the development of type 2 dia-
betes. Use of speciﬁc vitamin supplements may adopted into
this rational practice.
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